Cerenome, Inc.
Houston, Texas, United States · Biotechnology, Health Care, Health Diagnostics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent
Key facts
- Headquarters
- Houston, Texas, United States
- Employees
- 24
- Industries
- Biotechnology, Health Care, Health Diagnostics
- Status
- Public (CNSY)
- Website
- plustherapeutics.com
- Company page
Recent activity at Cerenome, Inc.
- : SEC 8-K (8.01): On September 30, 2026, Cerenome, Inc. updated its corporate presentation intended for meetings with investors and analysts. The presentation includes revised slides that are meant to communicate the company's latest strategic developments and financial information. This update demonstrates Cerenome's commitment to transparency and engagement with its stakeholders. The updated investor presentation is filed as Exhibit 99.1 in this report, providing detailed information as of the same date.
- : PLUS THERAPEUTICS
- : Cerenome, Inc. has secured up to $20 million in a financing facility with 3i Fund to support the commercial scale-up of its CNSide platform. The initial tranche of funding was received at closing with future tranches tied to milestones.
- : SEC 8-K (1.01):
- : SEC 8-K (1.01):
- : SEC 8-K (8.01): On April 20, 2026, Plus Therapeutics, Inc. received notice from The Nasdaq Stock Market LLC confirming that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). This follows a one-for-twenty-five reverse stock split effective April 2, 2026, aimed at boosting the stock price to meet Nasdaq listing standards. A press release announcing this compliance was issued on April 21, 2026, detailing the notification and the steps taken towards regulatory compliance. This event is significant as it ensures the company's continued listing on Nasdaq, allowing access to capital markets.
- : Plus Therapeutics Appoints Eric J. Daniels as Chief Development Officer
- : SEC 8-K (5.02): On April 9, 2026, Plus Therapeutics, Inc. announced the appointment of Dr. Eric J. Daniels as Chief Development Officer, effective April 20, 2026. Dr. Daniels will oversee the development of the Company’s pharmaceutical pipeline. Previously, he served as chief development officer at Kiora Pharmaceuticals and has an extensive background in biotechnology. Additionally, an Employment Agreement was entered into on April 8, 2026, granting Dr. Daniels an annual salary of $460,000, a target bonus of 40%, and stock options and restricted stock units, indicating a strategic investment in experienced leadership to enhance the company’s development initiatives.
- : SEC 8-K (8.01): On April 8, 2026, Plus Therapeutics, Inc. announced through a press release that their product REYOBIQ™ (rhenium Re186 obisbemeda) has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of pediatric malignant gliomas. This designation is significant as it provides various incentives for the development of therapies for rare diseases. The press release was attached as Exhibit 99.1 to the 8-K filing, indicating the strategic implications of this approval for the company's future developments and market positioning in pediatric oncology.
- : SEC 8-K (8.01): On March 31, 2026, Plus Therapeutics, Inc. issued a press release addressing significant corporate matters as referenced in Item 5.03 of the filing. This includes details surrounding a Certificate of Amendment to the Amended and Restated Certificate of Incorporation, which was officially filed on April 1, 2026. The press release's implications for the company suggest key operational changes that may positively affect future strategies and corporate governance. The release highlights essential milestones and may impact shareholder confidence due to alterations in the company's structure and compliance with regulatory requirements.
Cerenome, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2026 | Post-IPO Equity | $3.0M |
| Sep 2026 | Debt Financing | $20.0M |
| May 2024 | Post-IPO Equity | $18.0M |
| May 2020 | Seed | $300K |
Leadership
- Marc, President & CEO
- Mia, Associate Director, Human Resources
- Michelle, Vice President Clinical Operations
- Charles Huang, Vice President
- Eric J. Daniels, Chief Development Officer
- Michael Rosol, Chief Development Officer
- Marc Hedrick, President
Verified email and direct lines for Cerenome, Inc.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Cerenome, Inc. files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Cerenome, Inc. in the news
- Plus Therapeutics rebrands as Cerenome as it deepens AI strategy - Fierce Pharma (Jul 01, 2026)
- Cerenome Launches as an Integrated CNS Oncology Company - Yahoo Finance (Jul 31, 2026)
- Radiation therapy co. Cerenome plans major expansion at Hines' Levit Green campus - The Business Journals (Aug 20, 2026)
- CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView (Aug 03, 2026)
- Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding - GlobeNewswire (Jun 30, 2026)
- Plus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV) - Yahoo Finance (Jun 30, 2026)
- Cerenome (Nasdaq:CNSY) - Stock Analysis - Simply Wall St (Aug 04, 2026)
- Plus Therapeutics Secures National Coverage Agreement with - GlobeNewswire (Jun 25, 2026)
Companies similar to Cerenome, Inc.
- Jubilant Therapeutics · Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- CASI Pharmaceuticals · Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- Innovent Biologics (Innovent) · Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- PharmaCure · Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- YS Biopharma · Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
About Cerenome, Inc.: questions and answers
What does Cerenome, Inc. do?
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent
Where is Cerenome, Inc. headquartered?
Cerenome, Inc. is headquartered in Houston, Texas, United States.
How many employees does Cerenome, Inc. have?
Cerenome, Inc. has about 24 employees.
Has Cerenome, Inc. raised funding?
Yes. Fundz has recorded 4 funding events for Cerenome, Inc.. The most recent, Post-IPO Equity of $3.0M, was in Sep 2026.
Who leads Cerenome, Inc.?
Marc is a President & CEO at Cerenome, Inc..
What is the latest news on Cerenome, Inc.?
On Oct 02, 2026, SEC 8-K (8.01): On September 30, 2026, Cerenome, Inc. updated its corporate presentation intended for meetings with investors and analysts. The presentation includes revised slides that are meant to communicate the company's latest strategic developments and financial information. This update demons
Is Cerenome, Inc. a public company?
Yes. Cerenome, Inc. is publicly traded under the ticker CNSY.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy